IS2178B - Merktar frumueiturs-antrasýklín hliðstæður - Google Patents

Merktar frumueiturs-antrasýklín hliðstæður

Info

Publication number
IS2178B
IS2178B IS4734A IS4734A IS2178B IS 2178 B IS2178 B IS 2178B IS 4734 A IS4734 A IS 4734A IS 4734 A IS4734 A IS 4734A IS 2178 B IS2178 B IS 2178B
Authority
IS
Iceland
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
IS4734A
Other languages
English (en)
Other versions
IS4734A (is
Inventor
V. Schally Andrew
A. Nagy Attila
Cai Ren-Zhi
Original Assignee
Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2178(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Administrators Of The Tulane Educational Fund filed Critical Administrators Of The Tulane Educational Fund
Publication of IS4734A publication Critical patent/IS4734A/is
Publication of IS2178B publication Critical patent/IS2178B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS4734A 1995-11-27 1998-05-05 Merktar frumueiturs-antrasýklín hliðstæður IS2178B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (2)

Publication Number Publication Date
IS4734A IS4734A (is) 1998-05-05
IS2178B true IS2178B (is) 2006-12-15

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4734A IS2178B (is) 1995-11-27 1998-05-05 Merktar frumueiturs-antrasýklín hliðstæður
IS8567A IS2634B (is) 1995-11-27 2006-11-09 Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8567A IS2634B (is) 1995-11-27 2006-11-09 Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi

Country Status (27)

Country Link
US (2) US5843903A (is)
EP (2) EP1384710B1 (is)
JP (2) JP3987575B2 (is)
KR (2) KR100445754B1 (is)
CN (2) CN1137136C (is)
AT (2) ATE401305T1 (is)
AU (1) AU709539B2 (is)
BR (1) BR9611647B1 (is)
CA (2) CA2471775C (is)
CZ (1) CZ297297B6 (is)
DE (2) DE69630233T2 (is)
DK (2) DK1384710T3 (is)
EA (1) EA001372B1 (is)
ES (2) ES2205067T3 (is)
HK (1) HK1052920B (is)
HU (1) HU229870B1 (is)
IL (3) IL119691A (is)
IS (2) IS2178B (is)
MX (1) MX9804119A (is)
NO (2) NO324035B1 (is)
NZ (1) NZ322054A (is)
PL (3) PL187230B1 (is)
PT (2) PT1384710E (is)
SK (2) SK284672B6 (is)
UA (1) UA67722C2 (is)
WO (1) WO1997019954A1 (is)
ZA (1) ZA969709B (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
CA2350919A1 (en) 1998-11-13 2000-05-25 Cyclacel Limited Antennapedia homeodomain helix 3 derived translocation vectors
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
EP1235598A2 (en) * 1999-11-12 2002-09-04 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
JP2004517034A (ja) * 2000-04-26 2004-06-10 バイオシンセマ インコーポレーテッド （神経）ペプチド結合ｒｇｄ（ａｒｇ−ｇｌｙ−ａｓｐ）
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
CN1589151A (zh) * 2001-09-21 2005-03-02 图兰恩教育基金管理人 诊断或治疗性促生长素抑制素或铃蟾肽类似物的连接物及其用途
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
DE60331049D1 (de) 2002-03-01 2010-03-11 Univ Tulane Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US20060166871A1 (en) * 2002-05-21 2006-07-27 Daiichi Suntory Pharma., Ltd. Medical compositions containing ghrelin
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
CN101134119A (zh) 2002-05-24 2008-03-05 血管技术国际股份公司 用于涂覆医用植入物的组合物和方法
ATE416795T1 (de) 2002-09-26 2008-12-15 Angiotech Int Ag Perivaskuläre hüllen
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
EP2662087A1 (en) * 2003-04-22 2013-11-13 Ipsen Pharma Somatostatin vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
HRP20160631T1 (hr) * 2006-09-06 2016-07-15 Æterna Zentaris Gmbh Konjugati disorazola i njihovi derivati sa staničnovezajućim molekulama, novi derivati disorazola, postupci njihove pripreme i njihove uporabe
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
EP2240495B1 (en) 2008-02-01 2015-07-15 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
JP5647971B2 (ja) * 2008-04-11 2015-01-07 天津和美生物技▲術▼有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｂｉｏ−Ｔｅｃｈ Ｃｏ．Ｌｔｄ 高活性アントラサイクリン系抗生物質の誘導体、該誘導体の製造及び応用
EP2277884B1 (en) * 2008-04-11 2017-08-23 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
JP6067222B2 (ja) 2008-07-15 2017-01-25 ジェネンテック， インコーポレイテッド アントラサイクリン誘導体コンジュゲート、その調製方法及び抗腫瘍化合物としてのその用途
AU2010216372B2 (en) 2009-02-20 2013-06-20 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide Y receptor binding compound
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
JP6008864B2 (ja) 2010-12-02 2016-10-19 ナーヴィアノ メディカル サイエンシズ エス．アール．エル． モルホリニルアントラサイクリン誘導体の調製方法
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
AU2015284236B2 (en) 2014-06-30 2018-03-08 Tva (Abc), Llc Targeted conjugates and particles and formulations thereof
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
US20210402016A1 (en) * 2018-11-13 2021-12-30 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2023178449A1 (en) 2022-03-25 2023-09-28 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
EP0434960B1 (en) * 1989-12-19 1996-09-18 PHARMACIA S.p.A. Chiral 1,5-diiodo-2-methoxy or benzyloxy intermediates
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
EP0450480B1 (en) * 1990-04-06 1995-06-21 The Administrators of The Tulane Educational Fund Somatostatin Analogues
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
HK1052920B (zh) 2005-03-04
EP0863917A1 (en) 1998-09-16
ATE401305T1 (de) 2008-08-15
CN1137136C (zh) 2004-02-04
PL191781B1 (pl) 2006-07-31
EA001372B1 (ru) 2001-02-26
JP2007045845A (ja) 2007-02-22
JP4778405B2 (ja) 2011-09-21
EP1384710B1 (en) 2008-07-16
UA67722C2 (en) 2004-07-15
NZ322054A (en) 1999-04-29
IL119691A0 (en) 1997-02-18
EP0863917B1 (en) 2003-10-01
ZA969709B (en) 1997-08-25
KR20040037176A (ko) 2004-05-04
BR9611647B1 (pt) 2010-03-09
HU229870B1 (en) 2014-10-28
KR100445754B1 (ko) 2004-12-08
SK284392B6 (sk) 2005-03-04
IS8567A (is) 2006-11-09
PT863917E (pt) 2004-02-27
DE69637604D1 (de) 2008-08-28
CA2238574C (en) 2004-10-19
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
PT1384710E (pt) 2008-10-08
KR19990071672A (ko) 1999-09-27
BR9611647A (pt) 1999-02-23
PL326865A1 (en) 1998-10-26
CZ297297B6 (cs) 2006-11-15
ATE251179T1 (de) 2003-10-15
IL134685A (en) 2002-12-01
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
DE69630233D1 (de) 2003-11-06
EA199800492A1 (ru) 1998-12-24
HK1017363A1 (en) 1999-11-19
NO982252D0 (no) 1998-05-15
JP3987575B2 (ja) 2007-10-10
IS4734A (is) 1998-05-05
CA2471775C (en) 2008-01-29
JP2000502055A (ja) 2000-02-22
PL187230B1 (pl) 2004-06-30
SK62898A3 (en) 1999-06-11
AU709539B2 (en) 1999-09-02
PL188786B1 (pl) 2005-04-29
CZ135798A3 (cs) 1998-10-14
DK1384710T3 (da) 2008-11-17
AU7572296A (en) 1997-06-19
DK0863917T3 (da) 2004-01-19
US5843903A (en) 1998-12-01
WO1997019954A1 (en) 1997-06-05
SK284672B6 (sk) 2005-08-04
CA2238574A1 (en) 1997-06-05
ES2310222T3 (es) 2009-01-01
CN1202903A (zh) 1998-12-23
DE69630233T2 (de) 2004-08-05
NO324035B1 (no) 2007-07-30
US6184374B1 (en) 2001-02-06
IS2634B (is) 2010-06-15
CN1405127A (zh) 2003-03-26
HUP9903771A2 (hu) 2000-02-28
CA2471775A1 (en) 1997-06-05
NO982252L (no) 1998-05-15
CN1166597C (zh) 2004-09-15
HK1052920A1 (en) 2003-10-03
HUP9903771A3 (en) 2000-07-28
NO20051111L (no) 2005-03-01
EP1384710A1 (en) 2004-01-28
IL134685A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
IS2178B (is) Merktar frumueiturs-antrasýklín hliðstæður
SE9301911D0 (sv) New peptide derivatives
BR9813835A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromboembólica
BR9917080A (pt) Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
HU9600963D0 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IT1283782B1 (it) Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
ES2061442T3 (es) Peptidos.
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
ATE211719T1 (de) Korrosionsinhibitoren enthaltender injektionszement
TW333533B (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase
TW339325B (en) Novel azepane derivatives, process for the preparation thereof and pharmaceutical composition containing the same
ATE282608T1 (de) Chinoxalindionen
ES2195313T3 (es) Derivados de imino-aza-antraciclinona para el tratamiento de la amiloidosis.
EA199800289A1 (ru) Производные пептидов
MX9205408A (es) Metodo para tratar hipertension.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
AR015458A1 (es) Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene.
HUP9902556A2 (hu) Szinergetikus herbicid készítmény és eljárás annak alkalmazására
DK0674649T3 (da) Antiparasitiske midler
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola
EP1210948A4 (en) DRUGS FOR NERVOUS DISEASES
PT1100821E (pt) Compostos anti-inflammatorios derivados de lipocortina-1
ATE221897T1 (de) Inhibitoren der blutplättchen-aggregation, die c- terminale aminosäurereste mit aminergen seitenketten enthalten
TH53242A (th) อนุพันธ์ต่างๆ ของโคแลสแททิน 15
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii